The effects of reducing worry in patients with persecutory delusions: An explanatory randomised controlled trial

The Efficacy and Mechanism Evaluation Programme (MRC/NIHR) (UK)0 个研究点目标入组 150 人开始时间: 2011年4月20日最近更新: 2018年1月15日

适应症

试验速览

暂无简介。

•1. A current persecutory delusion as defined by Freeman and Garety (2000); scoring at least 3 on the conviction scale of the PSYRATS (Haddock et al, 1999)
•2. That the delusion has persisted for at least one month
•3. A clinical diagnosis of schizophrenia, schizoaffective disorder or delusional disorder (i.e. diagnosis of non-affective psychosis (F2) in the International Classification of Diseases and Diagnostic and Statistical Manual IV)
•4. A clinically significant level of worry, as indicated by scores above 44 on the Penn State Worry Questionnaire (see Startup and Erickson, 2006)
•5. Aged between 18 and 65
•6. Where major changes in medication are being made, entry to the study would not occur until at least a month after stabilisation of dosage

•1. A primary diagnosis of alcohol or substance dependency
•2. Organic syndrome or learning disability
•3. A command of spoken English inadequate for engaging in therapy
•4. Currently having individual cognitive behavioural therapy (CBT) (though previous CBT experience is not an exclusion)

发起方

The Efficacy and Mechanism Evaluation Programme (MRC/NIHR) (UK)